NASDAQ OMX

ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist

12.6.2017 15:00 | NASDAQ OMX

Dela

 

SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to support once-monthly subcutaneous (SC) administration of a GLP-1 receptor agonist (GLP-1RA) called PLX039 for the treatment of Type 2 diabetes (T2D). The work will be published in ACS Chemical Biology.

GLP-1RAs have emerged as an important standard-of-care drug class for the treatment of Type 2 diabetes and are projected to command a $12 Bill market by 2024. These agonists auto-regulate blood glucose concentration, have anti-obesity effects, and may reduce risks for adverse cardiovascular events in patients with T2D. Currently, there are three once- or twice- daily and three once-weekly GLP-1RAs approved by the FDA; an additional once-weekly agonist and a long-acting osmotic pump delivery system are in late stage trials.  Yet, poor medication adherence and persistence remain as major factors leading to failure of glycemic control in almost 50% of T2D patients. Now, ProLynx has used its half-life extension platform to develop a monthly-administered GLP-1RA. Compared to weekly-administered agonists, obvious benefits are believed to include greater patient convenience, compliance and persistence.

Daniel Santi, co-founder and President of ProLynx, said: "This is the first GLP-1RA that does not require huge doses of a drug meant for weekly administration to maintain therapeutic levels over a monthly period." Santi added: "PLX039 should find a dose-interval sweet-spot with its once-monthly administration. Some patients will find that a once-weekly dosing interval is too short, and will not want to have a long-acting osmotic pump implanted; for these patients, the once monthly GLP-1 receptor agonist PLX039 should be just right."

In the ProLynx half-life extension platform, a drug is tethered to hydrogel microspheres by a self-cleaving linker that is pre-programmed to release the drug at a pre-determined rate. After SC injection, the drug is slowly released from the microsphere depot into the systemic circulation. ProLynx attached their peptidic GLP-1RA - a stabilized analog of exenatide - to its hydrogel microspheres. After SC injection to rodents the GLP-1RA showed a serum half-life of one month. Monthly injections of the formulation in diabetic rats showed identical glucoregulatory effects as continuously infused exenatide, and simulation of the pharmacokinetics indicate it should serve well as a once-a-month treatment for T2D in humans.

About ProLynx. ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company may be found at  www.ProLynxllc.com.

Contact: 
Eric Schneider: Eric@ProLynxllc.com
Or BD@ProLynxllc.com
415-552-5306
 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProLynx LLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock29.6.2017 00:47Pressmeddelande

WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38,750,000. The offering is expected to close on or about July 5th, 2017, subject to customary closing conditions. Citigroup and Jefferies are acting as the book-running managers for the offering, and JMP Securities is acting as lead manager for the offering.   Minerva has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock, on the same terms and conditions. Minerva intends to use the net proceeds from the offering, together with its existing cash and investments, to fund part of th

Yandy.com Celebrates Baywatch Movie With Inspired-By Swim Collection28.6.2017 20:18Pressmeddelande

Yandy launches swim collection for domestic and international consumers PHOENIX, June 28, 2017 (GLOBE NEWSWIRE) -- Yandy.com, the leading online retailer of intimates, swimwear, and specialty apparel, announced today the top-performing swimsuits from its Baywatch ®  swimwear collection. To celebrate the film's U.S. release - Yandy.com produced, marketed and sold three swimwear designs inspired by looks worn by the movie's female lifeguard characters. The new Baywatch movie follows devoted lifeguard Mitch Buchannon (Dwayne Johnson) as he butts heads with a brash new recruit (Zac Efron). Together, they uncover a local criminal plot that threatens the future of the Bay. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d8a5-c973-4449-be85-6289c481671c Yandy's release of the Baywatch-inspired collection in May demonstrated an immediate interest among domestic consumers. No

Nasdaq's Directors Desk® and Boardvantage® to Introduce Board Assessments and Compliance Questionnaires28.6.2017 16:05Pressmeddelande

A Unique Collaboration between Nasdaq Corporate Solutions and the Center for Board Excellence NEW YORK and GREENSBORO, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Nasdaq Corporate Solutions, a business of Nasdaq, Inc. (Nasdaq:NDAQ), announced today a new partnership with The Center for Board Excellence (CBE), a provider of board assessments and compliance questionnaires. In the first phase of the partnership, Nasdaq Corporate Solutions will facilitate introductions for users of Directors Desk and Boardvantage - Nasdaq's board portal and meeting management solutions - to CBE's cloud-based corporate governance solutions including: board and committee assessments; director peer assessments; CEO and management evaluations; and directors' & officers' questionnaires. Later this year, the parties plan to offer an integrated workflow between Nasdaq's board portal solutions and CBE's EnGauge(TM) platform, making it even easier for users to elect to benefit fr

Datameer : Datameer Announces Industry-First Solution for Deploying AI to the Enterprise at Big Data Scale28.6.2017 15:00Pressmeddelande

New Datameer SmartAI democratizes data science within organizations by operationalizing deep learning models with enterprise scale and governance SAN FRANCISCO, June 28, 2017 (GLOBE NEWSWIRE) -- Furthering its mission to democratize data access within the enterprise, Datameer today unveiled SmartAI, an industry-first solution for operationalizing deep learning models directly within enterprise data lake environments securely and at scale. SmartAI finally allows enterprises to democratize data science, taking the deep learning work of data scientists from the lab to the business in production-ready scenarios that meet the big data security, governance and management standards IT requires. Now, business analysts can apply and execute trusted deep learning models against massive datasets from enterprise data lakes to drive better business outcomes. "With all the promise of data science and artificial intelligence, organizations have had difficulty delivering on its busi

Imperial Capital Hires Two Senior Sales Professionals Forming a Dedicated Convertible Institutional Sales Group28.6.2017 14:30Pressmeddelande

LOS ANGELES, June 28, 2017 (GLOBE NEWSWIRE) -- Imperial Capital Group, LLC ("Imperial Capital") announced today the hiring of James P. Kenney and Kevin Cadden, two senior institutional convertible sales professionals, forming a dedicated Convertible Sales Group, while adding to the franchise's continued credit sales & trading growth initiatives. The group will be responsible for expanding Imperial Capital's existing credit sales and trading business further into convertible products while working with a team of seasoned trading and research professionals to provide its institutional clients with valuable market color, trading ideas and excellent execution in both the fixed income and equity markets. "With the hiring of James and Kevin, we are able to provide our institutional clients with a team of veteran sales and trading professionals specializing in the convertible bond marketplace," said Tom Corcoran, President of Imperial Capital. "The team bri

AGF Management Limited Reports Strong Second Quarter 2017 Financial Results28.6.2017 14:00Pressmeddelande

30% growth in mutual fund gross sales compared to prior year quarter 50% of ranked AUM performed above median for the one-year period ended May 31, 2017, and 53% for the three-year period Achieved final close of InstarAGF Essential Infrastructure Fund (EIF) with $740 million in commitments Reported Diluted EPS of $0.16 compared to $0.12 in Q2 2016 TORONTO, June 28, 2017 (GLOBE NEWSWIRE) -- AGF Management Limited (AGF or the Company) today announced financial results for the second quarter ended May 31, 2017. Total assets under management (AUM) increased 8.0% to $36.4 billion compared to the same period in 2016, and up 3.7% compared to $35.1 billion as at February 28, 2017. AUM increased across all lines of business, including retail, private client, institutiona

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum